Serum Diazepam–Metabolite Validation Was Not an Impairment-Threshold Study

Written by

in

Analytical accuracy and clinical interpretation require separate evidence.

What the paper found

The UPLC-MS/MS method quantified diazepam, nordazepam and oxazepam in human serum. Validation examined extraction recovery, calibration, accuracy and precision, and the assay was applied to twenty-six therapeutic-monitoring specimens from patients with alcohol dependence.

Limits of the evidence

Performance in the tested serum conditions does not automatically validate whole blood, urine or postmortem specimens. A small clinical application cannot define a universal therapeutic or toxic interval. Active metabolites also complicate interpreting one concentration in isolation.

Implications for case review

Request the matrix, analytes and validation range before using a numerical result. A reliable measurement can still be insufficient to determine dose, timing or impairment. Clinical interpretation needs the individual medication course, tolerance, co-exposures and symptoms; the method’s precision does not supply those missing facts.

Source and related reading

Source: PMC12957979, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.

Related: Clobazam Interaction Review Shows Why Measuring the Active Metabolite Matters.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *